<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:23:52Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8762038" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8762038</identifier>
        <datestamp>2022-01-26</datestamp>
        <setSpec>bmjgroup</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Int J Gynecol Cancer</journal-id>
              <journal-id journal-id-type="iso-abbrev">Int J Gynecol Cancer</journal-id>
              <journal-id journal-id-type="hwp">ijgc</journal-id>
              <journal-id journal-id-type="publisher-id">ijgc</journal-id>
              <journal-title-group>
                <journal-title>International Journal of Gynecological Cancer</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1048-891X</issn>
              <issn pub-type="epub">1525-1438</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8762038</article-id>
              <article-id pub-id-type="pmcid">PMC8762038</article-id>
              <article-id pub-id-type="pmc-uid">8762038</article-id>
              <article-id pub-id-type="pmid">34799418</article-id>
              <article-id pub-id-type="pmid">34799418</article-id>
              <article-id pub-id-type="publisher-id">ijgc-2021-003017</article-id>
              <article-id pub-id-type="doi">10.1136/ijgc-2021-003017</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Trial</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1507</subject>
                  <subject>2423</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-66588917" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Marth</surname>
                    <given-names>Christian</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-90861480" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6802-5093</contrib-id>
                  <name>
                    <surname>Tarnawski</surname>
                    <given-names>Rafal</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                </contrib>
                <contrib id="author-66590578" contrib-type="author">
                  <name>
                    <surname>Tyulyandina</surname>
                    <given-names>Alexandra</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-68358653" contrib-type="author">
                  <name>
                    <surname>Pignata</surname>
                    <given-names>Sandro</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-70224842" contrib-type="author">
                  <name>
                    <surname>Gilbert</surname>
                    <given-names>Lucy</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib id="author-90861485" contrib-type="author">
                  <name>
                    <surname>Kaen</surname>
                    <given-names>Diego</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib id="author-90861486" contrib-type="author">
                  <name>
                    <surname>Rubio</surname>
                    <given-names>M Jesús</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib id="author-90861487" contrib-type="author">
                  <name>
                    <surname>Frentzas</surname>
                    <given-names>Sophia</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib id="author-87047401" contrib-type="author">
                  <name>
                    <surname>Beiner</surname>
                    <given-names>Mario</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib id="author-90861489" contrib-type="author">
                  <name>
                    <surname>Magallanes-Maciel</surname>
                    <given-names>Manuel</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib id="author-77594073" contrib-type="author">
                  <name>
                    <surname>Farrelly</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib id="author-70376504" contrib-type="author">
                  <name>
                    <surname>Choi</surname>
                    <given-names>Chel Hun</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                </contrib>
                <contrib id="author-68237846" contrib-type="author">
                  <name>
                    <surname>Berger</surname>
                    <given-names>Regina</given-names>
                  </name>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib id="author-90861493" contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Christine</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib id="author-90861494" contrib-type="author">
                  <name>
                    <surname>Vulsteke</surname>
                    <given-names>Christof</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib id="author-90861495" contrib-type="author">
                  <name>
                    <surname>Hasegawa</surname>
                    <given-names>Kosei</given-names>
                  </name>
                  <xref rid="aff17" ref-type="aff">17</xref>
                </contrib>
                <contrib id="author-70375655" contrib-type="author">
                  <name>
                    <surname>Braicu</surname>
                    <given-names>Elena Ioanna</given-names>
                  </name>
                  <xref rid="aff18" ref-type="aff">18</xref>
                </contrib>
                <contrib id="author-66460103" contrib-type="author">
                  <name>
                    <surname>Wu</surname>
                    <given-names>Xiaohua</given-names>
                  </name>
                  <xref rid="aff19" ref-type="aff">19</xref>
                </contrib>
                <contrib id="author-90861498" contrib-type="author">
                  <name>
                    <surname>McKenzie</surname>
                    <given-names>Jodi</given-names>
                  </name>
                  <xref rid="aff20" ref-type="aff">20</xref>
                </contrib>
                <contrib id="author-90861499" contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>John J</given-names>
                  </name>
                  <xref rid="aff21" ref-type="aff">21</xref>
                </contrib>
                <contrib id="author-66588857" contrib-type="author">
                  <name>
                    <surname>Makker</surname>
                    <given-names>Vicky</given-names>
                  </name>
                  <xref rid="aff22" ref-type="aff">22</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">AGO-Austria and Department of Obstetrics and Gynaecology</institution>, <institution>Medical University of Innsbruck</institution>, <addr-line content-type="city">Innsbruck</addr-line>, <country>Austria</country></aff>
              <aff id="aff2"><label>2</label><institution>Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch abd PGOG</institution>, <addr-line content-type="city">Gliwice</addr-line>, <country>Poland</country></aff>
              <aff id="aff3"><label>3</label><institution>CHRU Brest</institution>, <addr-line content-type="city">Brest</addr-line>, <country>France</country></aff>
              <aff id="aff4"><label>4</label><institution>NN Blokhin Russian Cancer Research Centre and IM Sechenov First Moscow State Medical University (Sechenov University)</institution>, <addr-line content-type="city">Moscow</addr-line>, <country>Russian Federation</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Department of Urology and Gynecology</institution>, <institution>Istituto Nazionale Tumori IRCCS Fondazione G Pascale and MITO</institution>, <addr-line content-type="city">Napoli</addr-line>, <country>Italy</country></aff>
              <aff id="aff6"><label>6</label><institution>McGill University Health Centre</institution>, <addr-line content-type="city">Montreal</addr-line>, <addr-line content-type="state">Quebec</addr-line>, <country>Canada</country></aff>
              <aff id="aff7"><label>7</label><institution>Centro Oncologico Riojano Integral and National University of La Rioja</institution>, <addr-line content-type="city">La Rioja</addr-line>, <country>Argentina</country></aff>
              <aff id="aff8"><label>8</label><institution>H Reina Sofía de Córdoba and GEICO Group</institution>, <addr-line content-type="city">Córdoba</addr-line>, <country>Spain</country></aff>
              <aff id="aff9"><label>9</label><institution>Monash Health and Monash University</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff>
              <aff id="aff10"><label>10</label><institution>Meir Medical Center and ISGO</institution>, <addr-line content-type="city">Kfar Saba</addr-line>, <country>Israel</country></aff>
              <aff id="aff11"><label>11</label><institution>Centro Oncológico Internacional</institution>, <addr-line content-type="city">Mexico City</addr-line>, <country>Mexico</country></aff>
              <aff id="aff12"><label>12</label><institution content-type="department">Cancer Research UK and University College London Cancer Trials Centre</institution>, <institution>Cancer Institute, University College London and NCRI</institution>, <addr-line content-type="city">London</addr-line>, <country>UK</country></aff>
              <aff id="aff13"><label>13</label><institution>Samsung Medical Center</institution>, <addr-line content-type="city">Seoul</addr-line>, <country>The Republic of Korea</country></aff>
              <aff id="aff14"><label>14</label><institution>AGO-Austria and University Hospital for Gynaecology and Obstetrics, Medical University of Innsbruck</institution>, <addr-line content-type="city">Innsbruck</addr-line>, <country>Austria</country></aff>
              <aff id="aff15"><label>15</label><institution>Texas Oncology - Woodlands</institution>, <addr-line content-type="city">The Woodlands</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff16"><label>16</label><institution content-type="department">Department of Medical Oncology</institution>, <institution>Integrated Cancer Center Ghent, AZ Maria Middelares Ghent and Center of Oncological Research, Integrated Personalized and Precision Oncology Network, University of Antwerp and BGOG</institution>, <addr-line content-type="city">Wilrijk</addr-line>, <country>Belgium</country></aff>
              <aff id="aff17"><label>17</label><institution>Saitama Medical University International Medical Center</institution>, <addr-line content-type="city">Hidaka</addr-line>, <addr-line content-type="state">Saitama</addr-line>, <country>Japan</country></aff>
              <aff id="aff18"><label>18</label><institution>Charité Universitätsmedizin Berlin and North Eastern German Society for Gynecologic Oncology (NOGGO)</institution>, <addr-line content-type="city">Berlin</addr-line>, <country>Germany</country></aff>
              <aff id="aff19"><label>19</label><institution>Fudan University Shanghai Cancer Center</institution>, <addr-line content-type="city">Shanghai</addr-line>, <country>China</country></aff>
              <aff id="aff20"><label>20</label><institution>Eisai Inc</institution>, <addr-line content-type="city">Woodcliff Lake</addr-line>, <addr-line content-type="state">New Jersey</addr-line>, <country>USA</country></aff>
              <aff id="aff21"><label>21</label><institution>Merck &amp; Co Inc</institution>, <addr-line content-type="city">Kenilworth</addr-line>, <addr-line content-type="state">New Jersey</addr-line>, <country>USA</country></aff>
              <aff id="aff22"><label>22</label><institution>Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical Center</institution>, <addr-line content-type="city">New York</addr-line>, <addr-line content-type="state">New York</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Professor Christian Marth, AGO-Austria and Department of Obstetrics and Gynaecology, Medical University of Innsbruck, Innsbruck, Austria; <email>Christian.marth@tirol-kliniken.at</email>
</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <volume>32</volume>
              <issue>1</issue>
              <fpage>93</fpage>
              <lpage>100</lpage>
              <history>
                <date date-type="accepted">
                  <day>13</day>
                  <month>10</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© IGCS and ESGO 2022. Re-use permitted under CC BY. Published by BMJ.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2021-11-19">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="ijgc-2021-003017.pdf"/>
              <abstract>
                <sec>
                  <title>Background</title>
                  <p>Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer (KEYNOTE-146/Study 111) after ≤2 previous lines of therapy. In a randomized phase 3 trial of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer (KEYNOTE-775/Study 309), after 1‒2 previous lines of therapy (including neoadjuvant/adjuvant), this combination improved objective response rates, progression-free survival, and overall survival compared with chemotherapy.</p>
                </sec>
                <sec>
                  <title>Primary Objective</title>
                  <p>To compare the efficacy and safety of first-line pembrolizumab plus lenvatinib versus paclitaxel plus carboplatin in patients with newly diagnosed stage III/IV or recurrent endometrial cancer, with measurable or radiographically apparent disease.</p>
                </sec>
                <sec>
                  <title>Study Hypothesis</title>
                  <p>Pembrolizumab plus lenvatinib is superior to chemotherapy with respect to progression-free survival and overall survival in patients with mismatch repair-proficient tumors and all patients (all-comers).</p>
                </sec>
                <sec>
                  <title>Trial Design</title>
                  <p>Phase 3, randomized (1:1), open-label, active-controlled trial. Patients will receive pembrolizumab intravenously every 3 weeks plus lenvatinib orally daily or paclitaxel plus carboplatin intravenously every 3 weeks, stratified by mismatch repair status (proficient vs deficient). Patients with mismatch repair-proficient tumors will be further stratified by Eastern Cooperative Oncology Group performance status (0/1), measurable disease (yes/no), and prior chemotherapy and/or chemoradiation (yes/no).</p>
                </sec>
                <sec>
                  <title>Major Inclusion/Exclusion Criteria</title>
                  <p>Adults with stage III/IV/recurrent histologically confirmed endometrial cancer that is measurable or radiographically apparent per blinded independent central review. Patients may have received previous chemotherapy only as neoadjuvant/adjuvant therapy and/or concurrently with radiation. Patients with carcinosarcoma (malignant mixed Müllerian tumor), endometrial leiomyosarcoma, or other high grade sarcomas, or endometrial stromal sarcomas were excluded.</p>
                </sec>
                <sec>
                  <title>Primary Endpoints</title>
                  <p>Progression-free and overall survival (dual primary endpoints).</p>
                </sec>
                <sec>
                  <title>Sample Size</title>
                  <p>About 875 patients.</p>
                </sec>
                <sec>
                  <title>Estimated Dates for Completing Accrual and Presenting Results</title>
                  <p>Enrollment is expected to take approximately 24 months, with presentation of results in 2022.</p>
                </sec>
                <sec>
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov, <ext-link xlink:href="NCT03884101" ext-link-type="uri">NCT03884101</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>uterine cancer</kwd>
                <kwd>endometrial neoplasms</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>Merck Sharp &amp; Dohme Corp.</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution>Eisai Inc.</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>editors-choice</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="s1">
              <title>INTRODUCTION</title>
              <p>Carcinoma of the uterine corpus, or endometrial cancer, makes up 2% of all new cancer cases,<xref rid="R1" ref-type="bibr">1</xref> and for most patients it is typically detected in the early stages when disease is confined to the uterus.<xref rid="R2" ref-type="bibr">2</xref> Five-year survival rates are high for patients with early-stage disease, and 5-year survival rates of 76% have been reported for all patients with endometrial cancer in Europe (all disease stages).<xref rid="R3" ref-type="bibr">3 4</xref> However, approximately 13% of patients experience recurrent disease.<xref rid="R5" ref-type="bibr">5</xref> The standard of care for patients with advanced or recurrent disease is multiagent systemic chemotherapy, including paclitaxel plus carboplatin in the first-line setting.<xref rid="R6" ref-type="bibr">6</xref> There is an urgent need to provide treatment options that yield better outcomes because the prognosis for these patients remains poor, with a 5-year survival rate of 17% in the recurrent metastatic setting.<xref rid="R2" ref-type="bibr">2</xref>
</p>
              <p>The combination of pembrolizumab and lenvatinib has emerged as an effective treatment for advanced, previously treated endometrial cancer. Pembrolizumab is an anti-programmed death 1 monoclonal antibody that blocks the interaction between programmed death 1 and programmed death ligands 1 and 2, and has been shown to be effective in the treatment of a variety of solid tumor types, including mismatch repair-deficient endometrial cancer.<xref rid="R7" ref-type="bibr">7 8</xref> Lenvatinib is a selective inhibitor of vascular endothelial growth factor receptors 1–3 and other receptor tyrosine kinases, such as fibroblast growth factor receptors 1–4, platelet-derived growth factor receptor α, KIT, and RET, and is a potent angiogenesis inhibitor.<xref rid="R9" ref-type="bibr">9</xref> It has also been shown to be an effective immunomodulator. Preclinical models have shown that lenvatinib decreases tumor-associated macrophages, increases T-cell populations, upregulates the type I interferon signaling pathway, and leads to activation of CD8-positive T cells. In preclinical models, lenvatinib in combination with anti-programmed death 1 therapy significantly suppressed and delayed tumor growth compared with either treatment alone.<xref rid="R9" ref-type="bibr">9</xref>
</p>
              <p>In a single-arm, phase 1b/2 trial of lenvatinib plus pembrolizumab, KEYNOTE-146/Study 111,<xref rid="R10" ref-type="bibr">10</xref> the combination of pembrolizumab and lenvatinib was associated with an objective response rate of 39.5% in patients with previously treated endometrial cancer (irrespective of mismatch repair status).<xref rid="R10" ref-type="bibr">10</xref> In a randomized phase 3 trial of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer (KEYNOTE-775/Study 309),<xref rid="R11" ref-type="bibr">11</xref> patients who had received one or two previous platinum based chemotherapy regimens (including in the neoadjuvant or adjuvant setting) had significantly prolonged progression-free and overall survival with pembrolizumab plus lenvatinib compared with physician’s treatment of choice (paclitaxel or doxorubicin) in both patients with mismatch repair-proficient disease (progression-free survival hazard ratio (HR) 0.60; overall survival HR 0.68) and in all enrolled patients (progression-free survival HR 0.56; overall survival HR 0.62).<xref rid="R11" ref-type="bibr">11</xref>
</p>
              <p>In the ENGOT-en9/LEAP-001 study (ClinicalTrials.gov NCT03884101; protocol MK-7902-001-05/E7080-G000-313/ENGOT-EN9; dated March 17, 2021), we hypothesize that the combination of pembrolizumab plus lenvatinib is superior to standard of care paclitaxel and carboplatin chemotherapy in the first-line setting with respect to progression-free survival and overall survival in both patients with mismatch repair-proficient endometrial cancer and all-comers (all enrolled patients with mismatch repair-proficient or mismatch repair-deficient tumors). In patients with mismatch repair-proficient endometrial cancer, superiority will be tested after non-inferiority to chemotherapy with respect to overall survival has been evaluated.</p>
            </sec>
            <sec id="s2">
              <title>METHODS AND ANALYSIS</title>
              <sec id="s2-1">
                <title>Trial Design</title>
                <p>ENGOT-en9/LEAP-001 is a phase 3, randomized, open-label, active-controlled trial of pembrolizumab in combination with lenvatinib compared with platinum doublet chemotherapy (paclitaxel and carboplatin). The first patient was enrolled on April 11, 2019. This study has completed recruitment and was conducted in 190 community clinics and academic hospitals in 22 countries in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study protocol and amendments were approved by institutional review boards or independent ethics committees at each study site. All patients provided written informed consent to the study investigator before undergoing any protocol-specific procedure.</p>
                <p>The study design is shown in <xref rid="F1" ref-type="fig">Figure 1</xref>. Patients were randomly assigned in a 1:1 ratio to receive either pembrolizumab 200 mg intravenously once every 3 weeks in combination with lenvatinib 20 mg orally daily or paclitaxel 175 mg/m<sup>2</sup> in combination with carboplatin area under the curve 6 mg/mL/min intravenously every 3 weeks. Study treatment was discontinued if patients experienced disease progression or unacceptable toxicity. Pembrolizumab must have been discontinued after 35 cycles, but lenvatinib could have been continued after pembrolizumab discontinuation. Patients could have received up to seven cycles of paclitaxel/carboplatin; however, chemotherapy treatment beyond seven cycles was permitted for patients who continued to derive clinical benefit. Lenvatinib dosing was reduced, interrupted, or discontinued according to protocol-specified guidelines for patients who experienced intolerable grade 2–3 adverse events or any grade 4 adverse events. Lenvatinib compliance was monitored based on the drug accountability documented by the site staff. Treatment for complications or adverse events could have been administered at the investigator’s discretion unless it was expected to interfere with the evaluation of, or interact with, study medication.</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <p>ENGOT-en9/LEAP-001 study design. <sup>a</sup>Treat until disease progression or unacceptable toxicity. Pembrolizumab must be stopped after 35 cycles, but lenvatinib may continue after stopping pembrolizumab. <sup>b</sup>Study will be fully enrolled when 612 patients with mismatch repair-proficient (pMMR) tumors and ~263 patients with mismatch repair-deficient (dMMR) tumors are recruited. <sup>c</sup>A lower starting dose of paclitaxel (135 mg/m<sup>2</sup>) and carboplatin (AUC 5 mg/mL/min) may be administered to patients at risk of developing toxicities due to previous pelvic/spine radiation. An AUC of 5 mg/mL/min dose of carboplatin may be administered in accordance with local practice. <sup>d</sup>Patients may receive up to seven cycles of paclitaxel/carboplatin; however, chemotherapy treatment beyond seven cycles may be permitted (with the sponsors’ approval) for patients who continue to derive clinical benefit. AUC, area under the curve (unit, mg/mL/min); ECOG, Eastern Cooperative Oncology Group; IV, intravenous; PS, performance status; QD, once daily; Q3W, every 3 weeks.</p>
                  </caption>
                  <graphic xlink:href="ijgc-2021-003017f01" position="float"/>
                </fig>
                <p>Funding and sponsorship for this research was provided by Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co Inc (Kenilworth, New Jersy, USA), and Eisai Inc (Woodcliff Lake, New Jersy, USA). The trial is being performed in collaboration with the European Network for Gynaecological Oncological Trial groups (ENGOT), which is a research network of the European Society of Gynaecological Oncology (ESGO).</p>
              </sec>
              <sec id="s2-2">
                <title>Participants</title>
                <p>Key patient eligibility criteria are listed in <xref rid="T1" ref-type="table">Table 1</xref>. Briefly, adults with stage III, IV, or recurrent histologically confirmed endometrial cancer that is measurable or non-measurable per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, but radiographically apparent as assessed by blinded independent central review, and Eastern Cooperative Oncology Group performance status ≤1 were eligible. Patients may have received prior chemotherapy only as neoadjuvant/adjuvant therapy and/or concurrently with radiation if the recurrence occurred ≥6 months after the last dose of chemotherapy. Patients with carcinosarcoma (malignant mixed Müllerian tumor), endometrial leiomyosarcoma, or other high-grade sarcomas, or endometrial stromal sarcomas, were excluded.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Key patient eligibility criteria</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Key inclusion criteria</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Key exclusion criteria</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Stage III, IV, or recurrent, histologically confirmed endometrial carcinoma with measurable or radiographically apparent disease*</p>
                            </list-item>
                            <list-item>
                              <p>Prior therapies may include chemotherapy (only if administered as neoadjuvant or adjuvant therapy and/or concurrently with radiation), radiation, or hormonal therapy (only if discontinued ≥1 week before randomization)</p>
                            </list-item>
                            <list-item>
                              <p>Provided archival tumor tissue or newly obtained biopsy of tumor for determination of mismatch repair status</p>
                            </list-item>
                            <list-item>
                              <p>Eastern Cooperative Oncology Group performance status of 0/1</p>
                            </list-item>
                          </list>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Carcinosarcoma, endometrial leiomyosarcoma, or other high grade sarcomas, or endometrial stromal sarcomas</p>
                            </list-item>
                            <list-item>
                              <p>Additional malignancies that have progressed or required active treatment in the last 3 years†</p>
                            </list-item>
                            <list-item>
                              <p>Gastrointestinal conditions that might affect absorption of lenvatinib</p>
                            </list-item>
                            <list-item>
                              <p>Active infection requiring systemic treatment</p>
                            </list-item>
                            <list-item>
                              <p>Previous therapy with any treatment targeting vascular endothelial growth factor-directed angiogenesis; anti-PD-1, anti-PD-L1, or anti-PD-L2 agents; or any agent directed at another stimulatory or co-inhibitory T cell receptor</p>
                            </list-item>
                            <list-item>
                              <p>Inadequate organ function</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1_FN1">
                      <p>*Disease may be either measurable or non-measurable per Response Evaluation Criteria in Solid Tumors v1.1 but must be radiographically apparent by blinded independent central review.</p>
                    </fn>
                    <fn id="T1_FN2">
                      <p>†Not including basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative therapy.</p>
                    </fn>
                    <fn id="T1_FN3">
                      <p>PD-1, programmed death 1; PD-L1, programmed death ligand 1; PD-L2, programmed death ligand 2.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2-3">
                <title>Endpoints</title>
                <p>The objective of this study was to compare the efficacy and safety of first-line pembrolizumab in combination with lenvatinib versus paclitaxel plus carboplatin in patients with newly diagnosed, stage III, IV, or recurrent endometrial cancer. The dual primary endpoints were progression-free survival per RECIST v1.1 by blinded independent central review (modified to follow a maximum of 10 target lesions and five target lesions per organ) and overall survival in patients with mismatch repair-proficient tumors and in all patients (all-comers). Progression-free survival was defined as the time from randomization to first documented disease progression or death due to any cause, whichever occurred first. Overall survival was defined as the time from randomization to death due to any cause. Patient survival status is assessed routinely, including after disease progression or start of new anticancer therapy. Mismatch repair status was assessed by a central laboratory (Neogenomics, Fort Myers, Florida, USA) by immunohistochemistry (Ventana, Tuscon, Arizona, USA) using archived tumor tissue or a fresh biopsy before randomization.</p>
                <p>Secondary endpoints were objective response rate per RECIST v1.1 by blinded independent central review in patients with mismatch repair-proficient tumors and in all-comers, health related quality of life in patients with mismatch repair-proficient tumors and in all-comers, and safety and tolerability in all-comers. Objective response was defined as a confirmed complete or partial response. Health-related quality of life is evaluated using the mean change from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‒Core 30 global health status/quality of life score. Safety and tolerability were assessed by clinical review of adverse events, laboratory tests, vital signs, and ECG measurements throughout the study until 90 days (120 days for serious adverse events) after the last dose of study treatment, or until 30 days after the last dose if new anticancer therapy was initiated.</p>
                <p>Key exploratory endpoints included duration of response, disease control rate, and clinical benefit rate per RECIST v1.1 by blinded independent central review in patients with mismatch repair-proficient tumors and in all-comers. Duration of response was defined as the time from first documented response to first documented disease progression or death, whichever occurred first. Disease control was defined as the best overall response of complete or partial response or of stable disease ≥7 weeks after randomization. Clinical benefit was defined as best overall response of complete or partial response or of stable disease with duration ≥23 weeks after randomization.</p>
              </sec>
              <sec id="s2-4">
                <title>Sample Size</title>
                <p>Sample size was calculated to allow hypothesis testing of the dual primary endpoints of progression-free survival and overall survival to be well powered. The study is considered to be fully enrolled when 612 mismatch repair-proficient participants have enrolled. At the time of enrollment completion, approximately 875 total participants are expected to be enrolled, with 612 mismatch repair-proficient participants and approximately 263 mismatch repair-deficient participants.</p>
              </sec>
              <sec id="s2-5">
                <title>Randomization and Blinding</title>
                <p>Patients were randomized 1:1 to receive pembrolizumab in combination with lenvatinib or to receive paclitaxel in combination with carboplatin. Randomization was conducted using an interactive response technology system. Randomization was first stratified by mismatch repair status (proficient vs deficient) with patients with mismatch repair-proficient tumors further stratified by Eastern Cooperative Oncology Group performance status (0 vs 1), measurable disease (yes vs no), and previous chemotherapy and/or chemoradiation (yes vs no). This was an open-label study and therefore, no blinding was performed.</p>
              </sec>
              <sec id="s2-6">
                <title>Statistical Methods</title>
                <p>All randomized patients will be included in the efficacy analysis population and all patients who received ≥1 dose of study treatment will be included in the safety analysis population. The primary endpoints of progression-free and overall survival will be estimated using the non-parametric Kaplan–Meier method. Treatment differences will be assessed using the stratified log rank test, and the magnitude of treatment difference will be estimated using a stratified Cox proportional hazards model with the Efron method of tie handling. The stratification factors used for randomization will be applied to the stratified log-rank test and the stratified Cox model.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>DISCUSSION</title>
              <p>Several studies have evaluated the use of anti-programmed death 1 or anti-programmed death ligand 1 monoclonal antibodies as monotherapy in patients with previously treated, advanced, or recurrent endometrial cancer (<xref rid="T2" ref-type="table">Table 2</xref>), including pembrolizumab,<xref rid="R8" ref-type="bibr">8 12</xref> dostarlimab (anti-programmed death 1),<xref rid="R13" ref-type="bibr">13 14</xref> durvalumab (anti-programmed death ligand 1),<xref rid="R15" ref-type="bibr">15</xref> and avelumab (anti-programmed death ligand 1).<xref rid="R16" ref-type="bibr">16</xref> Across these studies, objective response rates ranged between 27% and 57% in patients with mismatch repair-deficient tumors and between 3% and 14% in patients with mismatch repair-proficient tumors.<xref rid="R8" ref-type="bibr">8 12–16</xref> Lenvatinib monotherapy was also evaluated in a phase 2 trial of 133 patients with recurrent endometrial cancer with an objective response rate of 14.3% with a manageable safety profile.<xref rid="R17" ref-type="bibr">17</xref>
</p>
              <table-wrap position="float" id="T2">
                <label>Table 2</label>
                <caption>
                  <p>Clinical trials evaluating anti-programmed death 1/programmed death ligand 1 therapies in patients with previously treated endometrial cancer</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Study</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Phase</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Therapy</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Disease</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Previous therapy</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Biomarkers</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">N</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Objective response rate (%)</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">KEYNOTE-028<xref rid="R12" ref-type="bibr">12</xref>
</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">1b</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Pembrolizumab<break/>(anti-PD-1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Locally advanced or metastatic endometrial cancer</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients had disease that had progressed after standard therapy, or for which no standard therapy exists, or for which standard therapy is not appropriate</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">PD-L1-positive</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">24 (23 in efficacy analysis)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">13.0% (RECIST v1.1 by investigator review)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">KEYNOTE-158<xref rid="R8" ref-type="bibr">8</xref>
</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">2</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Pembrolizumab<break/>(anti-PD-1)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Unresectable and/or metastatic incurable endometrial carcinoma</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients had disease that had progressed on or was intolerant to previous standard therapy</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">MSI-H/dMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">49</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">57.1% (RECIST v1.1 by independent central radiologic review)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="2" colspan="1">GARNET<xref rid="R14" ref-type="bibr">14</xref>
</td>
                      <td align="char" char="." valign="top" rowspan="2" colspan="1">1</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Dostarlimab<break/>(anti-PD-1)</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Recurrent or advanced endometrial cancer</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Patients had disease that had progressed during or after chemotherapy with ≤2 previous lines of therapy</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">dMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">110</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">45.5% (RECIST v1.1 by blinded independent central review)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">pMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">144</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">13.9% (immune-related RECIST by investigator assessment)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="2" colspan="1">PHAEDRA (ANZGOG1601)<xref rid="R15" ref-type="bibr">15</xref>
</td>
                      <td align="char" char="." valign="top" rowspan="2" colspan="1">2</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Durvalumab<break/>(anti-PD-L1)</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Advanced endometrial cancer</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients had disease that had progressed after 0–3 previous lines of chemotherapy</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">dMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">35</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">40% (immune-related RECIST)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients had disease that had progressed after 1–3 previous lines of chemotherapy</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">pMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">36</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">3% (immune-related RECIST)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="2" colspan="1">NCT02912572<xref rid="R16" ref-type="bibr">16</xref>
</td>
                      <td align="char" char="." valign="top" rowspan="2" colspan="1">2</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Avelumab<break/>(anti-PD-L1)</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Recurrent endometrial cancer</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Patients had received ≥1 previous lines of chemotherapy</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">dMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">15</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">26.7% (RECIST v1.1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">pMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">16</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">6.25% (RECIST v1.1)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="3" colspan="1">KEYNOTE-146/<break/>Study 111<xref rid="R10" ref-type="bibr">10</xref>
</td>
                      <td align="char" char="." valign="top" rowspan="3" colspan="1">1b/2</td>
                      <td align="left" valign="top" rowspan="3" colspan="1">Pembrolizumab + lenvatinib<break/>(anti-PD-1 + tyrosine kinase inhibitor)</td>
                      <td align="left" valign="top" rowspan="3" colspan="1">Advanced endometrial cancer</td>
                      <td align="left" valign="top" rowspan="3" colspan="1">Patients had received ≤2 previous lines of systemic therapy (≥2 lines allowed at sponsor’s discretion)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">dMMR or pMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">124</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">39.5% (immune-related RECIST by investigator assessment)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">dMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">11</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">63.6% (immune-related RECIST by investigator assessment)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">pMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">94</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">36.2% (immune-related RECIST by investigator assessment)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="2" colspan="1">KEYNOTE-775/<break/>Study 309<xref rid="R11" ref-type="bibr">11</xref>
</td>
                      <td align="char" char="." valign="top" rowspan="2" colspan="1">3</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Pembrolizumab + lenvatinib<break/>(anti-PD-1 + tyrosine kinase inhibitor) vs<break/>doxorubicin or paclitaxel</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Advanced endometrial cancer</td>
                      <td align="left" valign="top" rowspan="2" colspan="1">Patients had received 1‒2 previous platinum-based chemotherapy regimens (including neoadjuvant/adjuvant)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">dMMR or pMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">827</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">31.9% vs 14.7% (RECIST v1.1 by blinded independent central review)</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">pMMR</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">697</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">30.3% vs 15.1% (RECIST v1.1 by blinded independent central review)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T2_FN1">
                    <p>dMMR, mismatch repair-deficient; MSI-H, microsatellite instability high; PD-1, programmed death 1; PD-L1, programmed death ligand 1; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Clinical trials evaluating pembrolizumab plus lenvatinib in patients with endometrial cancer demonstrated objective response rates of 32–40%.<xref rid="R10" ref-type="bibr">10 11</xref> Results were similar among patients with mismatch repair-proficient tumors (30‒36%). In a single-arm, phase 1b/2 trial (KEYNOTE-146/Study 111),<xref rid="R10" ref-type="bibr">10</xref> this combination was associated with an objective response rate of 39.5% in a cohort of patients with endometrial cancer, most of whom had received previous therapy.<xref rid="R10" ref-type="bibr">10</xref> In the KEYNOTE-775/Study 309 trial that evaluated pembrolizumab in combination with lenvatinib compared with physician’s treatment of choice (paclitaxel or doxorubicin chemotherapy), progression-free survival, overall survival, and objective response rate were all significantly improved in the pembrolizumab and lenvatinib arm compared with the physician’s treatment of choice (paclitaxel or doxorubicin chemotherapy) in patients with mismatch repair-proficient tumors (n=697; median progression-free survival 6.6 vs 3.8 months (HR 0.60); median overall survival 17.4 vs 12.0 months (HR 0.68); objective response rate 30.3% vs 15.1% (p&lt;0.0001)) and in all-comers (n=827; median progression-free survival 7.2 vs 3.8 months (HR 0.56); median overall survival 18.3 vs 11.4 months (HR, 0.62); objective response rate 31.9% vs 14.7% (p&lt;0.0001)).<xref rid="R11" ref-type="bibr">11</xref> Based on the results of the confirmatory KEYNOTE-775/Study 309 trial, the US Food and Drug Administration accelerated approval for pembrolizumab plus lenvatinib in this setting was converted to a full approval.<xref rid="R7" ref-type="bibr">7</xref>
</p>
              <p>Given the positive results from KEYNOTE-146/Study 111 and KEYNOTE-775/Study 309, we are optimistic that the results of the ENGOT-en9/LEAP-001 study will demonstrate a similar clear progression-free survival and overall survival benefit of pembrolizumab in combination with lenvatinib in the first-line treatment of patients with primary advanced or recurrent endometrial cancer. This trial has the potential to define the new standard of first-line treatment in recurrent endometrial cancer. There are also other ongoing trials evaluating programmed death 1/programmed death ligand 1 antibody-based combinations in the first-line setting in patients with primary advanced or recurrent endometrial cancer (<xref rid="T3" ref-type="table">Table 3</xref>). Data from the ENGOT-en9/LEAP-001 study will be presented at upcoming scientific meetings, submitted to a peer reviewed journal for publication, and posted on trial registries.</p>
              <table-wrap position="float" id="T3">
                <label>Table 3</label>
                <caption>
                  <p>Select ongoing clinical trials evaluating anti-programmed death 1/programmed death ligand 1 therapies in patients with primary advanced or recurrent endometrial cancer</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Study</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Phase</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Therapy</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Disease</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Previous therapy</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Biomarkers</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">N</td>
                      <td align="left" valign="bottom" rowspan="1" colspan="1">Location</td>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">ENGOT-en6/NSGO-RUBY<xref rid="R18" ref-type="bibr">18</xref>
<break/>NCT03981796</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">3</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Dostarlimab (anti-PD-1) + carboplatin + paclitaxel followed by dostarlimab with or without niraparib vs<break/>placebo + carboplatin + paclitaxel followed by placebo</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">First recurrent or primary stage III–IV endometrial cancer</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients had received no previous systemic chemotherapy; previous neoadjuvant/adjuvant chemotherapy permitted if recurrence ≥6 months</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">MSI-H or MSS</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">~470</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Europe, North America</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">ENGOT-en7/AtTEnd<xref rid="R19" ref-type="bibr">19</xref>
<break/>NCT03603184</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">3</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Paclitaxel + carboplatin + atezolizumab (anti-PD-L1) followed by atezolizumab vs<break/>paclitaxel + carboplatin + placebo followed by placebo</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Newly diagnosed, advanced stage III–IV or recurrent endometrial cancer</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients had received one previous line of chemotherapy if upfront/adjuvant and platinum-free interval ≥6 months</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">None</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">~550</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Australia, Europe, Japan, New Zealand</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">ENGOT-en9/LEAP-001 (current study)<break/>NCT03884101</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">3</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Pembrolizumab + lenvatinib<break/>(anti-PD-1 + tyrosine kinase inhibitor) vs<break/>paclitaxel + carboplatin</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stage III, IV, or recurrent endometrial cancer</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients may have received previous chemotherapy (as neoadjuvant/adjuvant therapy and/or concurrently with radiation) radiation, or hormonal therapy (completed ≥1 week prior)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">dMMR or pMMR</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">~875</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Asia, Australia, Europe, North America, South America</td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" rowspan="1" colspan="1">NRG-GY018<break/>NCT03914612</td>
                      <td align="char" char="." valign="top" rowspan="1" colspan="1">3</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Pembrolizumab (anti-PD-1) + paclitaxel + carboplatin followed by pembrolizumab vs<break/>placebo + paclitaxel + carboplatin followed by placebo</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Stage III–IVB or recurrent endometrial cancer</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">Patients may have received prior adjuvant chemotherapy (completed ≥12 months prior), radiation therapy (completed ≥4 weeks prior), or hormonal therapy (completed ≥3 weeks prior)</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">PD-L1-positive or negative; dMMR or pMMR</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">~810</td>
                      <td align="left" valign="top" rowspan="1" colspan="1">North America</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="T3_FN1">
                    <p>dMMR, mismatch repair-deficient; MSI-H, microsatellite instability high; MSS, microsatellite stable; PD-1, programmed death 1; PD-L1, programmed death ligand 1; pMMR, mismatch repair-proficient.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
            </sec>
          </body>
          <back>
            <ack>
              <p>The authors thank Stephen Keefe, MD (Merck &amp; Co Inc, Kenilworth, New Jersey, USA), for contributions to the trial design and Shan Yang, PhD (Merck &amp; Co Inc), for contributions to the statistical design and methodology. Medical writing assistance was provided by Rozena Varghese, PharmD, CMPP (ICON plc, North Wales, Pennsylvania, USA). This assistance was funded by Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co Inc.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Twitter:</bold> @CVulsteke</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> All authors are members of the steering committee, are contributing to the trial, and have reviewed, revised, and approved the manuscript for publication.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> Funding and sponsorship for this research was provided by Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co Inc (Kenilworth, New Jersey, USA), and Eisai Inc (Woodcliff Lake, New Jersey, USA). The study sponsors were involved in the study design, in the writing of the report, and in the decision to submit the paper for publication. JJL and JM are contacts for Merck &amp; Co and Eisai Inc, respectively. VM is supported in part by NIH/NCI Cancer Center Support Grant P30 CA008748.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> CM: funded research, EU, FWF, AstraZeneca, and Roche; honoraria/expenses, Roche, Novartis, Amgen, Merck, Pharmamar, AstraZeneca, Tesaro, and GSK; consulting/advisory board, Roche, Novartis, Amgen, Merck, AstraZeneca, Pfizer, Pharmamar, Cerulean, Vertex, GSK, Seagen, and Eisai. AT: funded research, AstraZeneca, Roche, MSD, and RUSSCO; honoraria/expenses, AstraZeneca, Roche, MSD, Eisai, Biocad, and RUSSCO; consulting/advisory board, AstraZeneca, Pfizer, MSD, Eisai, Tesaro, and Biocad. SP: honoraria, MSD, Eisai, GSK, AstraZeneca, Clovis, Pfizer, Pharmamar, and Roche. LG: institutional grants from AstraZeneca, Pfizer, Merck Sharp &amp; Dohme, Karyopharm, Tesaro, IMV, Alkermes, Clovis, ImmunoGen Inc, Roche, Mersana, Esperas, Novocure GmbH, and OncoQuest Pharmaceuticals; advisory boards, AstraZeneca, GSK, Eisai, Eisai-Merck, and Alkermes. DK: clinical trials, Roche, Lilly Oncology, Clovis, MSD, Abbvie, Takeda, Novartis, Pfizer, Array BioPharma Inc, Servier, Nektar Therapeutics, Merck Healthcare KGaA, and GlaxoSmithKline; consultancy, Roche, Boehringer Ingelheim, Pfizer, MSD, BMS, Novartis, AstraZeneca, Raffo-tecnofarma, Varifarma, and Bayer. MJR: consulting/advisory board, MSD, AstraZeneca, GSK, Pharmamar, and Roche. SF: consulting/advisory board, Akesobio; honoraria/expenses, Amgen. MM-M: consulting/advisory board, Roche, Eli-Lilly, BMS, AstraZeneca, Teva, Amgen, Bayer, and Pfizer. RB: travel expenses, Clovis Oncology, Roche, and MSD. CV: study funding for present publication from MSD; institutional grant, MSD; consulting fees, Janssen-Cilag, Roche, GSK, Atheneum Partners, Astellas Pharma, MSD, BMS, and Leo-Pharma; payment or honoraria for presentations, Janssen Cilag, Leo Pharma, and Bayer; payment or honoraria for advisory boards, Janssen Cilag, Leo Pharma, MSD, GSK, and AstraZeneca; support for travel, Roche and Pfizer. KH: funded research, MSD, Ono, Takeda, Daiichi-Sankyo, and Eisai; honoraria, Takeda, Chugai, Kyowa-Kirin, Genmab, AstraZeneca, and MSD; consulting/advisory board, MSD, Eisai, and Takeda. EB: funded research, EU, DLR, AstraZeneca, Roche Diagnostics, and Bayer; honoraria/expenses, Roche, Merck, AstraZeneca, Tesaro, GSK, Clovis, Roche Diagnostics, Molecular Health, and Eisai; consulting/advisory board, Roche, Eisai, Merck, AstraZeneca, GSK, and Clovis. JM: employee of Eisai Inc, Woodcliff Lake, New Jersey, USA. JJL: employee of Merck Sharp &amp; Dohme Corp, a subsidiary of Merck &amp; Co Inc, Kenilworth, New Jersey, USA and stockholder in Merck &amp; Co. VM: study support (all funding to institution)/consultant/advisory board membership, Merck, Eisai, Karyopharm, AstraZeneca, Clovis, Moreo, Takeda, Zymeworks, and Genentech; supported in part by the NIH/NCI Cancer Center Support grant P30 CA008748.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Commissioned; internally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company’s clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data sharing website (available at: <ext-link xlink:href="http://engagezone.msd.com/ds_documentation.php" ext-link-type="uri">http://engagezone.msd.com/ds_documentation.php</ext-link>) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the US and EU or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.</p>
            </sec>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sung</surname><given-names>H</given-names></string-name>, <string-name><surname>Ferlay</surname><given-names>J</given-names></string-name>, <string-name><surname>Siegel</surname><given-names>RL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source><year>2021</year>;<volume>71</volume>:<fpage>209</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33538338?><pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="book"><person-group person-group-type="editor"><string-name><surname>Howlader</surname><given-names>N</given-names></string-name>, <string-name><surname>Noone</surname><given-names>AM</given-names></string-name>, <string-name><surname>Krapcho</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>, eds. <source>SEER Cancer Statistics Review, 1975-2017</source>. <publisher-loc>Bethesda, MD</publisher-loc>: <publisher-name>National Cancer Institute</publisher-name>, <year>2020</year>. <uri xlink:href="https://seer.cancer.gov/csr/1975_2017/">https://seer.cancer.gov/csr/1975_2017/</uri></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sant</surname><given-names>M</given-names></string-name>, <string-name><surname>Chirlaque Lopez</surname><given-names>MD</given-names></string-name>, <string-name><surname>Agresti</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study</article-title>. <source>Eur J Cancer</source><year>2015</year>;<volume>51</volume>:<fpage>2191</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejca.2015.07.022</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/26421822?><pub-id pub-id-type="pmid">26421822</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Concin</surname><given-names>N</given-names></string-name>, <string-name><surname>Matias-Guiu</surname><given-names>X</given-names></string-name>, <string-name><surname>Vergote</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma</article-title>. <source>Int J Gynecol Cancer</source><year>2021</year>;<volume>31</volume>:<fpage>12</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1136/ijgc-2020-002230</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33397713?><pub-id pub-id-type="pmid">33397713</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fung-Kee-Fung</surname><given-names>M</given-names></string-name>, <string-name><surname>Dodge</surname><given-names>J</given-names></string-name>, <string-name><surname>Elit</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Follow-up after primary therapy for endometrial cancer: a systematic review</article-title>. <source>Gynecol Oncol</source><year>2006</year>;<volume>101</volume>:<fpage>520</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2006.02.011</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/16556457?><pub-id pub-id-type="pmid">16556457</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>National Comprehensive Cancer Network (NCCN)</collab></person-group>. <source>NCCN clinical practice guidelines in oncology (NCCN guidelines) uterine neoplasms</source>. <publisher-name>Version 1</publisher-name>, <year>2021</year>.</mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>KEYTRUDA® (pembrolizumab)</collab></person-group>. <source>Full prescribing information</source>. <publisher-loc>Whitehouse Station, NJ, USA</publisher-loc>: <publisher-name>Merck Sharp &amp; Dohme Corp</publisher-name>, <year>2021</year>.</mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marabelle</surname><given-names>A</given-names></string-name>, <string-name><surname>Le</surname><given-names>DT</given-names></string-name>, <string-name><surname>Ascierto</surname><given-names>PA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.19.02105</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31682550?><pub-id pub-id-type="pmid">31682550</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kato</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tabata</surname><given-names>K</given-names></string-name>, <string-name><surname>Kimura</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway</article-title>. <source>PLoS One</source><year>2019</year>;<volume>14</volume>:<elocation-id>e0212513</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0212513</pub-id><?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/30811474?><pub-id pub-id-type="pmid">30811474</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Makker</surname><given-names>V</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>MH</given-names></string-name>, <string-name><surname>Aghajanian</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>2981</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.19.02627</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/32167863?><pub-id pub-id-type="pmid">32167863</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Makker</surname><given-names>V</given-names></string-name>, <string-name><surname>Colombo</surname><given-names>N</given-names></string-name>, <string-name><surname>Casado Herraez</surname><given-names>A</given-names></string-name></person-group>. <source>A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician’s choice in patients with advanced endometrial cancer</source>. <publisher-name>Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer</publisher-name>, <year>March 19-25, 2021</year>.</mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ott</surname><given-names>PA</given-names></string-name>, <string-name><surname>Bang</surname><given-names>Y-J</given-names></string-name>, <string-name><surname>Berton-Rigaud</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study</article-title>. <source>J Clin Oncol</source><year>2017</year>;<volume>35</volume>:<fpage>2535</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2017.72.5952</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/28489510?><pub-id pub-id-type="pmid">28489510</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oaknin</surname><given-names>A</given-names></string-name>, <string-name><surname>Tinker</surname><given-names>AV</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial</article-title>. <source>JAMA Oncol</source><year>2020</year>;<volume>6</volume>:<fpage>1766</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1001/jamaoncol.2020.4515</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/33001143?><pub-id pub-id-type="pmid">33001143</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Oaknin</surname><given-names>A</given-names></string-name>, <string-name><surname>Gilbert</surname><given-names>L</given-names></string-name>, <string-name><surname>Tinker</surname><given-names>AV</given-names></string-name>, <etal>et al</etal></person-group>. <source>Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the garnet study</source>. <publisher-name>Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer</publisher-name>, <year>March 19-25, 2021</year>.</mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Antill</surname><given-names>YC</given-names></string-name>, <string-name><surname>Kok</surname><given-names>PS</given-names></string-name>, <string-name><surname>Robledo</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601)</article-title>. <source>J Clin Oncol</source><year>2019</year>;<volume>37</volume>:<elocation-id>5501</elocation-id>. <pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.5501</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Konstantinopoulos</surname><given-names>PA</given-names></string-name>, <string-name><surname>Luo</surname><given-names>W</given-names></string-name>, <string-name><surname>Liu</surname><given-names>JF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer</article-title>. <source>J Clin Oncol</source><year>2019</year>;<volume>37</volume>:<fpage>2786</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.19.01021</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31461377?><pub-id pub-id-type="pmid">31461377</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vergote</surname><given-names>I</given-names></string-name>, <string-name><surname>Powell</surname><given-names>MA</given-names></string-name>, <string-name><surname>Teneriello</surname><given-names>MG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Second-line lenvatinib in patients with recurrent endometrial cancer</article-title>. <source>Gynecol Oncol</source><year>2020</year>;<volume>156</volume>:<fpage>575</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.ygyno.2019.12.039</pub-id>
<?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31955859?><pub-id pub-id-type="pmid">31955859</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirza</surname><given-names>MR</given-names></string-name>, <string-name><surname>Coleman</surname><given-names>RL</given-names></string-name>, <string-name><surname>Hanker</surname><given-names>LC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>ENGOT-EN6/NSGO-RUBY: a phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC)</article-title>. <source>JCO</source><year>2020</year>;<volume>38</volume>:<elocation-id>TPS6107</elocation-id>. <pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.TPS6107</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colombo</surname><given-names>N</given-names></string-name>, <string-name><surname>Barretina-Ginesta</surname><given-names>MP</given-names></string-name>, <string-name><surname>Beale</surname><given-names>PJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>AtTEnd/ENGOT-en7: a multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer</article-title>. <source>J Clin Oncol</source><year>2019</year>;<volume>37</volume>:<elocation-id>TPS5608</elocation-id>. <pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.TPS5608</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
